A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer

Trial Profile

A Randomised, Open-label Phase III Study to Assess Efficacy and Safety of Bevacizumab in Combination With Capecitabine as First-line Treatment for Elderly Patients With Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AVEX
  • Sponsors Roche
  • Most Recent Events

    • 23 Dec 2013 Study start date changed to July 2007 as reported by ClinicalTrials.gov record.
    • 09 Sep 2013 Results published in Lancet Oncology.
    • 18 Mar 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top